ADCs 24 Years On: A Snapshot of the Landscape

Abstract: Antibody–drug conjugate development continues apace, with multiple agents highlighted at the recent American Society of Clinical Oncology 2024 Annual Meeting. TROP2-targeting sacituzumab tirumotecan, in combination with PD-(L)1 blockade, showed promise for non–small cell lung cancer, as did c-Met–targeting telisotuzumab vedotin. Meanwhile, M9140, ABBV-706, and MRG004A—aimed at CEACAM5, SEZ6, and TF, respectively—appeared safe and active, particularly in colorectal cancer, small-cell lung cancer, and pancreatic adenocarcinoma.